Similarly, using the filtering criteria of |FC| ≥ 1.5 and a P-value < 0.05, based on “m6A site abundance”, 800 differential m6A-methylated sites in the BMSCs were identified in the T2DM group when compared with the control; of which 44 were m6A hypermethylated sites (Table S3; including the 3’UTR of SPEN, CDS of INF2, CDS of ZFYVE19, CDS of ZNF394, and 3’UTR of BORCS8) and 756 were m6A hypomethylated sites (Table S4; including the 3’UTR of METTL14, 3’UTR of YTHDC2, CDS of YTHDF2, CDS of TRMT61B, and 3’UTR of RARRES3). This evidence concerns the gene METTL14 and type 2 diabetes mellitus.